Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 5/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | ITGAL | P20701 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CRHBP | P24387 | 2/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1265859 | 0.81 | NOTUM (0.47) | MAOBMAOANOTUMSMN1; SMN2NPC1 | |
| SCHEMBL769591 | 0.78 | MAP3K14 (0.42) | MAOBMAOAGRM5ITGB2ICAM1 | |
| SCHEMBL27203819 | 0.78 | PTGS2 (0.39) | MAOBTYK2MAOAGRM5TP53 | |
| SCHEMBL13506273 | 0.78 | MAOB (0.39) | MAOBMAOAGRM5ITGB2ICAM1 | |
| SCHEMBL12431229 | 0.78 | ITGB1 (0.40) | MAOBMAOAGRM5ITGB2ICAM1 | |
| SCHEMBL23226116 | 0.78 | ITGB2 (0.37) | MAOBTYK2NOTUMITGB2ICAM1 | |
| SCHEMBL30401806 | 0.78 | ITGB1 (0.40) | MAOBMAOAGRM5ITGB2ICAM1 | |
| SCHEMBL9923781 | 0.78 | MAOA (0.46) | MAOBMAOAGRM5ITGB2ICAM1 | |
| SCHEMBL14052938 | 0.77 | ALDH1A1 (0.40) | MAOBMAOAGRM5ALDH1A1 | |
| SCHEMBL30953643 | 0.77 | ALDH1A1 (0.40) | MAOBMAOAGRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583856-B2 | Inhibitors of protein kinase A | BLUEPRINT MEDICINES CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| US-20240132490-A1 | INHIBITORS OF PROTEIN KINASE A | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2022204150-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | BLUE OAK PHARMACEUTICALS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022165402-A1 | INHIBITORS OF PROTEIN KINASE A | BLUEPRINT MEDICINES CORPORATION (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-3623371-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | Axovant Sciences GmbH (CH) | 2020-03-18 | — | — | EP | disclosed |
| EP-3233087-B1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (DE) | 2019-10-02 | — | — | EP | disclosed |
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-01-22 | — | — | US | disclosed |
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-01-22 | — | — | US | disclosed |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (CH) | 2017-12-28 | — | — | US | disclosed |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (CH) | 2017-12-28 | — | — | US | disclosed |
| EP-1874772-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007107827-A1 | CHROMANE DERIVATIVES | RAQUALIA PHARMA INC. (JP) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219237-A1 | Chromane Derivatives | PFIZER INC | 2007-09-20 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007072146-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS ACID PUMP INHIBITORS | PFIZER JAPAN INC. (JP) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142448-A1 | Chromane Substituted Benzimidazole Derivatives | PFIZER INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2006134460-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006108103-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219237-A1 | Chromane Derivatives | HRH2, HRH1, CHRM1 | MAOB 1943/4885TYK2 3852/4885MAOA 2646/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | MAOB 38/4885TYK2 1373/4885MAOA 85/4885 |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | MAOB 943/4885TYK2 1690/4885MAOA 1365/4885 |
| US-12583856-B2 | Inhibitors of protein kinase A | CSNK1A1, CSNK1A1L, CSNK1G1 | MAOB 2446/4885TYK2 845/4885MAOA 1241/4885 |
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | CHRNA7, CHRNA6, CHRNA5 | MAOB 2539/4885TYK2 3309/4885MAOA 1974/4885 |
| US-20070142448-A1 | Chromane Substituted Benzimidazole Derivatives | HRH2, HRH4, HRH1 | MAOB 2180/4885TYK2 3211/4885MAOA 2377/4885 |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA6, CHRNA5 | MAOB 2606/4885TYK2 3342/4885MAOA 2098/4885 |
| US-20240132490-A1 | INHIBITORS OF PROTEIN KINASE A | PRKCA, MAP3K6, MAP3K1 | MAOB 1906/4885TYK2 511/4885MAOA 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.